Your browser doesn't support javascript.
loading
Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53.
Kaczorowski, Adam; Tolstov, Yanis; Falkenstein, Michael; Vasioukhin, Valeri; Prigge, Elena-Sophie; Geisler, Christine; Kippenberger, Maximilian; Nientiedt, Cathleen; Ratz, Leonie; Kuryshev, Vladimir; Herpel, Esther; Kristiansen, Glen; Sültmann, Holger; Stenzinger, Albrecht; Doeberitz, Magnus von Knebel; Hohenfellner, Markus; Duensing, Anette; Duensing, Stefan.
Afiliação
  • Kaczorowski A; Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Tolstov Y; Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Falkenstein M; Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Vasioukhin V; Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview, Avenue N C3-168, Seattle, 98109, Washington.
  • Prigge ES; Department of Applied Tumor Biology, Institute of Pathology, University Hospital, Heidelberg, and Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
  • Geisler C; Department of Urology, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
  • Kippenberger M; Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Nientiedt C; Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany; Department of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Ratz L; Cancer Genome Research, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Kuryshev V; Cancer Genome Research, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Herpel E; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, D-69120, Heidelberg, Germany; Tissue Bank of the National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
  • Kristiansen G; Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany.
  • Sültmann H; Cancer Genome Research, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, D-69120, Heidelberg, Germany.
  • Doeberitz MVK; Department of Applied Tumor Biology, Institute of Pathology, University Hospital, Heidelberg, and Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
  • Hohenfellner M; Department of Urology, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
  • Duensing A; Department of Urology, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany; Precision Oncology of Urological Malignancies, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120
  • Duensing S; Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany; Department of Urology, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany. El
Urol Oncol ; 38(9): 736.e1-736.e10, 2020 09.
Article em En | MEDLINE | ID: mdl-32674955
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Rearranjo Gênico / Regulação Neoplásica da Expressão Gênica / Proteína Supressora de Tumor p53 Limite: Aged / Animals / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Rearranjo Gênico / Regulação Neoplásica da Expressão Gênica / Proteína Supressora de Tumor p53 Limite: Aged / Animals / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha